Around 40% of breast cancers, especially those that are hormone receptor-positive (HR+) and HER2-negative (HER2-), begin with a change or mutation in the PIK3CA gene. This mutation happens only in cancer cells and not in healthy cells. Like a switch stuck in the “on” position, a PIK3CA mutation signals cancer cells to keep growing, even […] The post Breast Cancer Breakthroughs Episode 16: On the Horizon of PI3K Pathway Inhibition appeared first on Susan G. Komen®.| Susan G. Komen®